Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-07-02

AUTHORS

Zubin Punthakee, Michael E. Miller, Debra L. Simmons, Matthew C. Riddle, Faramarz Ismail-Beigi, David J. Brillon, Richard M. Bergenstal, Peter J. Savage, Irene Hramiak, Joseph F. Largay, Ajay Sood, Hertzel C. Gerstein, for the ACCORD Group of Investigators

ABSTRACT

Aims/hypothesisWe aimed to determine the persistence of glycaemic control 1 year after a limited period of intensive glycaemic management of type 2 diabetes.Methods4119 ACCORD Trial participants randomised to target HbA1c <6.0% (42 mmol/mol) for 4.0 ± 1.2 years were systematically transitioned to target HbA1c 7.0–7.9% (53–63 mmol/mol) and followed for an additional 1.1 ± 0.2 years. Characteristics of participants with HbA1c <6.5% (48 mmol/mol) or ≥6.5% at transition were compared. Changes in BMI and glucose-lowering medications were compared between those ending with HbA1c <6.5% vs ≥6.5%. Poisson models were used to assess the independent effect of attaining HbA1c <6.5% before transition on ending with HbA1c <6.5%.ResultsParticipants with pre-transition HbA1c <6.5% were older with shorter duration diabetes and took less insulin but more non-insulin glucose-lowering agents than those with higher HbA1c. A total of 823 participants achieved a final HbA1c <6.5%, and had greater post-transition reductions in BMI, insulin dose and secretagogue and acarbose use than those with higher HbA1c (p < 0.0001). HbA1c <6.5% at transition predicted final HbA1c <6.5% (crude RR 4.9 [95% CI 4.0, 5.9]; RR 3.9 [95% CI 3.2, 4.8] adjusted for demographics, co-interventions, pre-intervention HbA1c, BMI and glucose-lowering medication, and post-transition change in both BMI and glucose-lowering medication). Progressively lower pre-transition HbA1c levels were associated with a greater likelihood of maintaining a final HbA1c of <6.5%. Follow-up duration was not associated with post-transition rise in HbA1c.Conclusions/interpretationTime-limited intensive glycaemic management using a combination of agents that achieves HbA1c levels below 6.5% in established diabetes is associated with glycaemic control more than 1 year after therapy is relaxed. More... »

PAGES

2030-2037

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00125-014-3318-5

DOI

http://dx.doi.org/10.1007/s00125-014-3318-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006512049

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24985147


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycated Hemoglobin A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, McMaster University, 1280 Main St W., L8S 4K1, Hamilton, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.25073.33", 
          "name": [
            "Department of Medicine, McMaster University, 1280 Main St W., L8S 4K1, Hamilton, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Punthakee", 
        "givenName": "Zubin", 
        "id": "sg:person.0771130323.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771130323.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.241167.7", 
          "name": [
            "Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Michael E.", 
        "id": "sg:person.014063322564.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014063322564.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VA Salt Lake City Health Care System, Salt Lake City, UT, USA", 
          "id": "http://www.grid.ac/institutes/grid.280807.5", 
          "name": [
            "Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT, USA", 
            "VA Salt Lake City Health Care System, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Simmons", 
        "givenName": "Debra L.", 
        "id": "sg:person.01351344021.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351344021.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA", 
          "id": "http://www.grid.ac/institutes/grid.5288.7", 
          "name": [
            "Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riddle", 
        "givenName": "Matthew C.", 
        "id": "sg:person.01030201361.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030201361.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland VA Medical Center, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.410349.b", 
          "name": [
            "Department of Medicine, Case Western Reserve University, Cleveland, OH, USA", 
            "Cleveland VA Medical Center, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ismail-Beigi", 
        "givenName": "Faramarz", 
        "id": "sg:person.010732071677.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010732071677.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology, Weill Cornell Medical College of Cornell University, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Division of Endocrinology, Weill Cornell Medical College of Cornell University, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brillon", 
        "givenName": "David J.", 
        "id": "sg:person.01227535066.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227535066.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International Diabetes Center at Park Nicollet, Minneapolis, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417226.4", 
          "name": [
            "International Diabetes Center at Park Nicollet, Minneapolis, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bergenstal", 
        "givenName": "Richard M.", 
        "id": "sg:person.01007144437.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007144437.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.419635.c", 
          "name": [
            "National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Savage", 
        "givenName": "Peter J.", 
        "id": "sg:person.013715322252.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013715322252.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Western University, London, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.39381.30", 
          "name": [
            "Department of Medicine, Western University, London, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hramiak", 
        "givenName": "Irene", 
        "id": "sg:person.01050764017.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050764017.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.410711.2", 
          "name": [
            "Division of Endocrinology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Largay", 
        "givenName": "Joseph F.", 
        "id": "sg:person.0651704421.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651704421.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Louis Stokes VA Medical Center, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.410349.b", 
          "name": [
            "Department of Medicine, Case Western Reserve University, Cleveland, OH, USA", 
            "Louis Stokes VA Medical Center, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sood", 
        "givenName": "Ajay", 
        "id": "sg:person.01014260473.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014260473.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, McMaster University, 1280 Main St W., L8S 4K1, Hamilton, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.25073.33", 
          "name": [
            "Department of Medicine, McMaster University, 1280 Main St W., L8S 4K1, Hamilton, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gerstein", 
        "givenName": "Hertzel C.", 
        "id": "sg:person.0622502703.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622502703.19"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "for the ACCORD Group of Investigators", 
        "type": "Person"
      }
    ], 
    "datePublished": "2014-07-02", 
    "datePublishedReg": "2014-07-02", 
    "description": "Aims/hypothesisWe aimed to determine the persistence of glycaemic control 1\u00a0year after a limited period of intensive glycaemic management of type 2 diabetes.Methods4119 ACCORD Trial participants randomised to target HbA1c <6.0% (42\u00a0mmol/mol) for 4.0\u2009\u00b1\u20091.2\u00a0years were systematically transitioned to target HbA1c 7.0\u20137.9% (53\u201363\u00a0mmol/mol) and followed for an additional 1.1\u2009\u00b1\u20090.2\u00a0years. Characteristics of participants with HbA1c <6.5% (48\u00a0mmol/mol) or \u22656.5% at transition were compared. Changes in BMI and glucose-lowering medications were compared between those ending with HbA1c <6.5% vs \u22656.5%. Poisson models were used to assess the independent effect of attaining HbA1c <6.5% before transition on ending with HbA1c <6.5%.ResultsParticipants with pre-transition HbA1c <6.5% were older with shorter duration diabetes and took less insulin but more non-insulin glucose-lowering agents than those with higher HbA1c. A total of 823 participants achieved a final HbA1c <6.5%, and had greater post-transition reductions in BMI, insulin dose and secretagogue and acarbose use than those with higher HbA1c (p\u2009<\u20090.0001). HbA1c <6.5% at transition predicted final HbA1c <6.5% (crude RR 4.9 [95% CI 4.0, 5.9]; RR 3.9 [95% CI 3.2, 4.8] adjusted for demographics, co-interventions, pre-intervention HbA1c, BMI and glucose-lowering medication, and post-transition change in both BMI and glucose-lowering medication). Progressively lower pre-transition HbA1c levels were associated with a greater likelihood of maintaining a final HbA1c of <6.5%. Follow-up duration was not associated with post-transition rise in HbA1c.Conclusions/interpretationTime-limited intensive glycaemic management using a combination of agents that achieves HbA1c levels below 6.5% in established diabetes is associated with glycaemic control more than 1\u00a0year after therapy is relaxed.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00125-014-3318-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2430195", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2430201", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2430200", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2430196", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2430198", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2430199", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2706661", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2430197", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2706671", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "57"
      }
    ], 
    "keywords": [
      "type 2 diabetes", 
      "final HbA1c", 
      "intensive glycaemic management", 
      "glycaemic control", 
      "glycaemic management", 
      "short-duration diabetes", 
      "ACCORD clinical trial", 
      "glucose-lowering medications", 
      "glucose-lowering agents", 
      "Aims/hypothesisWe", 
      "combination of agents", 
      "characteristics of participants", 
      "acarbose use", 
      "insulin dose", 
      "higher HbA1c", 
      "less insulin", 
      "clinical trials", 
      "HbA1c", 
      "trial participants", 
      "diabetes", 
      "independent effects", 
      "greater likelihood", 
      "BMI", 
      "control 1", 
      "participants", 
      "years", 
      "durable changes", 
      "medications", 
      "hypothesisWe", 
      "therapy", 
      "management", 
      "agents", 
      "secretagogues", 
      "insulin", 
      "dose", 
      "ResultsParticipants", 
      "intensive management", 
      "trials", 
      "limited period", 
      "levels", 
      "total", 
      "control", 
      "Poisson model", 
      "duration", 
      "changes", 
      "period", 
      "likelihood", 
      "persistence", 
      "reduction", 
      "effect", 
      "use", 
      "combination", 
      "rise", 
      "characteristics", 
      "model", 
      "transition", 
      "glycaemic control 1", 
      "Methods4119 ACCORD Trial participants", 
      "ACCORD Trial participants", 
      "pre-transition HbA1c", 
      "duration diabetes", 
      "more non-insulin glucose-lowering agents", 
      "non-insulin glucose-lowering agents", 
      "greater post-transition reductions", 
      "post-transition reductions", 
      "post-transition rise", 
      "Conclusions/interpretationTime-limited intensive glycaemic management", 
      "interpretationTime-limited intensive glycaemic management"
    ], 
    "name": "Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial", 
    "pagination": "2030-2037", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006512049"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00125-014-3318-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24985147"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00125-014-3318-5", 
      "https://app.dimensions.ai/details/publication/pub.1006512049"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_632.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00125-014-3318-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00125-014-3318-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00125-014-3318-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00125-014-3318-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00125-014-3318-5'


 

This table displays all metadata directly associated to this object as RDF triples.

304 TRIPLES      21 PREDICATES      105 URIs      97 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00125-014-3318-5 schema:about N344e95714d20407786a33109f2600a31
2 N40edcca8fbf3437fb3835f60bfbca538
3 N4fd83570994f48f8ab509531973a32d2
4 N5b5c2f2e6ccd4f438fe6efc0cc8adbbf
5 N6802575bb6e0480ba95b3cebc2f4e325
6 N6d914eafdc8a4fad832c73a6f1f1ccd6
7 N8cd1140687bd43d5bff70c115459772a
8 Nae85a7ee2cda45a8b542b561ca930dc2
9 Nc60ef3bcd56d453892114a3db1bfacc8
10 Ne550130ba78f481cb9dbe39f4d257ca7
11 Nfcb18d252fee471e818309b5dbf8d5cb
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author Nfbb46f076e4646d9b7aa1857c7a237cc
15 schema:datePublished 2014-07-02
16 schema:datePublishedReg 2014-07-02
17 schema:description Aims/hypothesisWe aimed to determine the persistence of glycaemic control 1 year after a limited period of intensive glycaemic management of type 2 diabetes.Methods4119 ACCORD Trial participants randomised to target HbA1c <6.0% (42 mmol/mol) for 4.0 ± 1.2 years were systematically transitioned to target HbA1c 7.0–7.9% (53–63 mmol/mol) and followed for an additional 1.1 ± 0.2 years. Characteristics of participants with HbA1c <6.5% (48 mmol/mol) or ≥6.5% at transition were compared. Changes in BMI and glucose-lowering medications were compared between those ending with HbA1c <6.5% vs ≥6.5%. Poisson models were used to assess the independent effect of attaining HbA1c <6.5% before transition on ending with HbA1c <6.5%.ResultsParticipants with pre-transition HbA1c <6.5% were older with shorter duration diabetes and took less insulin but more non-insulin glucose-lowering agents than those with higher HbA1c. A total of 823 participants achieved a final HbA1c <6.5%, and had greater post-transition reductions in BMI, insulin dose and secretagogue and acarbose use than those with higher HbA1c (p < 0.0001). HbA1c <6.5% at transition predicted final HbA1c <6.5% (crude RR 4.9 [95% CI 4.0, 5.9]; RR 3.9 [95% CI 3.2, 4.8] adjusted for demographics, co-interventions, pre-intervention HbA1c, BMI and glucose-lowering medication, and post-transition change in both BMI and glucose-lowering medication). Progressively lower pre-transition HbA1c levels were associated with a greater likelihood of maintaining a final HbA1c of <6.5%. Follow-up duration was not associated with post-transition rise in HbA1c.Conclusions/interpretationTime-limited intensive glycaemic management using a combination of agents that achieves HbA1c levels below 6.5% in established diabetes is associated with glycaemic control more than 1 year after therapy is relaxed.
18 schema:genre article
19 schema:inLanguage en
20 schema:isAccessibleForFree true
21 schema:isPartOf Nb62ffec180604aba8268c05a5da79858
22 Nfbbc2c6fd6a649778ddfca4d8f8d07df
23 sg:journal.1001482
24 schema:keywords ACCORD Trial participants
25 ACCORD clinical trial
26 Aims/hypothesisWe
27 BMI
28 Conclusions/interpretationTime-limited intensive glycaemic management
29 HbA1c
30 Methods4119 ACCORD Trial participants
31 Poisson model
32 ResultsParticipants
33 acarbose use
34 agents
35 changes
36 characteristics
37 characteristics of participants
38 clinical trials
39 combination
40 combination of agents
41 control
42 control 1
43 diabetes
44 dose
45 durable changes
46 duration
47 duration diabetes
48 effect
49 final HbA1c
50 glucose-lowering agents
51 glucose-lowering medications
52 glycaemic control
53 glycaemic control 1
54 glycaemic management
55 greater likelihood
56 greater post-transition reductions
57 higher HbA1c
58 hypothesisWe
59 independent effects
60 insulin
61 insulin dose
62 intensive glycaemic management
63 intensive management
64 interpretationTime-limited intensive glycaemic management
65 less insulin
66 levels
67 likelihood
68 limited period
69 management
70 medications
71 model
72 more non-insulin glucose-lowering agents
73 non-insulin glucose-lowering agents
74 participants
75 period
76 persistence
77 post-transition reductions
78 post-transition rise
79 pre-transition HbA1c
80 reduction
81 rise
82 secretagogues
83 short-duration diabetes
84 therapy
85 total
86 transition
87 trial participants
88 trials
89 type 2 diabetes
90 use
91 years
92 schema:name Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial
93 schema:pagination 2030-2037
94 schema:productId N1b5d30a3ba754f88b3e2551041aa1a09
95 N722f7c5926834a0981b4ef82ed3c4794
96 Nb40965e552194edb9cb2d4b7f2451bae
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006512049
98 https://doi.org/10.1007/s00125-014-3318-5
99 schema:sdDatePublished 2021-12-01T19:31
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N0381a563d4b046b3846e69e0f2666a80
102 schema:url https://doi.org/10.1007/s00125-014-3318-5
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N0381a563d4b046b3846e69e0f2666a80 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 N0b999b9e783b49f78a5a90596bd7773d rdf:first sg:person.01050764017.81
109 rdf:rest N43edbeeed3eb441c990cc58b237f062a
110 N0fde4122c9714c1d89474c933381b2b5 rdf:first sg:person.01014260473.71
111 rdf:rest Nf1bb5dd1d8a840d0848aec371df0dd87
112 N1b5d30a3ba754f88b3e2551041aa1a09 schema:name dimensions_id
113 schema:value pub.1006512049
114 rdf:type schema:PropertyValue
115 N3129efd646154030b070ef62d9905602 rdf:first sg:person.010732071677.28
116 rdf:rest N9dc693140b064de3a50d4d95b2bd1d77
117 N344e95714d20407786a33109f2600a31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Adult
119 rdf:type schema:DefinedTerm
120 N40edcca8fbf3437fb3835f60bfbca538 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Hypoglycemic Agents
122 rdf:type schema:DefinedTerm
123 N43edbeeed3eb441c990cc58b237f062a rdf:first sg:person.0651704421.35
124 rdf:rest N0fde4122c9714c1d89474c933381b2b5
125 N4fd83570994f48f8ab509531973a32d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Glycated Hemoglobin A
127 rdf:type schema:DefinedTerm
128 N5b5c2f2e6ccd4f438fe6efc0cc8adbbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Female
130 rdf:type schema:DefinedTerm
131 N6802575bb6e0480ba95b3cebc2f4e325 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Aged
133 rdf:type schema:DefinedTerm
134 N6d02ac57904a4b0ab96ad873a14cd35c rdf:first sg:person.01351344021.39
135 rdf:rest Nf2eb2197b3954b8a9ed078e4ba12d9dd
136 N6d914eafdc8a4fad832c73a6f1f1ccd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Treatment Outcome
138 rdf:type schema:DefinedTerm
139 N722f7c5926834a0981b4ef82ed3c4794 schema:name pubmed_id
140 schema:value 24985147
141 rdf:type schema:PropertyValue
142 N77c51deac9d34ecab1c42f9d0acfba06 rdf:first sg:person.01007144437.64
143 rdf:rest N9f4f59d75214484886849a83c540ff7a
144 N84a9072dc9c04093a01f1851b18a4e8b rdf:first Nd034ea9225e0455dbd9345db7d726fdb
145 rdf:rest rdf:nil
146 N8cd1140687bd43d5bff70c115459772a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Male
148 rdf:type schema:DefinedTerm
149 N9276a41812e7441c8c4584f27cf535cc rdf:first sg:person.014063322564.84
150 rdf:rest N6d02ac57904a4b0ab96ad873a14cd35c
151 N9dc693140b064de3a50d4d95b2bd1d77 rdf:first sg:person.01227535066.58
152 rdf:rest N77c51deac9d34ecab1c42f9d0acfba06
153 N9f4f59d75214484886849a83c540ff7a rdf:first sg:person.013715322252.30
154 rdf:rest N0b999b9e783b49f78a5a90596bd7773d
155 Nae85a7ee2cda45a8b542b561ca930dc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Blood Glucose
157 rdf:type schema:DefinedTerm
158 Nb40965e552194edb9cb2d4b7f2451bae schema:name doi
159 schema:value 10.1007/s00125-014-3318-5
160 rdf:type schema:PropertyValue
161 Nb62ffec180604aba8268c05a5da79858 schema:issueNumber 10
162 rdf:type schema:PublicationIssue
163 Nc60ef3bcd56d453892114a3db1bfacc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Diabetes Mellitus, Type 2
165 rdf:type schema:DefinedTerm
166 Nd034ea9225e0455dbd9345db7d726fdb schema:familyName for the ACCORD Group of Investigators
167 rdf:type schema:Person
168 Ne550130ba78f481cb9dbe39f4d257ca7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Middle Aged
170 rdf:type schema:DefinedTerm
171 Nf1bb5dd1d8a840d0848aec371df0dd87 rdf:first sg:person.0622502703.19
172 rdf:rest N84a9072dc9c04093a01f1851b18a4e8b
173 Nf2eb2197b3954b8a9ed078e4ba12d9dd rdf:first sg:person.01030201361.33
174 rdf:rest N3129efd646154030b070ef62d9905602
175 Nfbb46f076e4646d9b7aa1857c7a237cc rdf:first sg:person.0771130323.51
176 rdf:rest N9276a41812e7441c8c4584f27cf535cc
177 Nfbbc2c6fd6a649778ddfca4d8f8d07df schema:volumeNumber 57
178 rdf:type schema:PublicationVolume
179 Nfcb18d252fee471e818309b5dbf8d5cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Humans
181 rdf:type schema:DefinedTerm
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
186 schema:name Clinical Sciences
187 rdf:type schema:DefinedTerm
188 sg:grant.2430195 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
189 rdf:type schema:MonetaryGrant
190 sg:grant.2430196 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
191 rdf:type schema:MonetaryGrant
192 sg:grant.2430197 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
193 rdf:type schema:MonetaryGrant
194 sg:grant.2430198 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
195 rdf:type schema:MonetaryGrant
196 sg:grant.2430199 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
197 rdf:type schema:MonetaryGrant
198 sg:grant.2430200 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
199 rdf:type schema:MonetaryGrant
200 sg:grant.2430201 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
201 rdf:type schema:MonetaryGrant
202 sg:grant.2706661 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
203 rdf:type schema:MonetaryGrant
204 sg:grant.2706671 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-014-3318-5
205 rdf:type schema:MonetaryGrant
206 sg:journal.1001482 schema:issn 0012-186X
207 1432-0428
208 schema:name Diabetologia
209 schema:publisher Springer Nature
210 rdf:type schema:Periodical
211 sg:person.01007144437.64 schema:affiliation grid-institutes:grid.417226.4
212 schema:familyName Bergenstal
213 schema:givenName Richard M.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007144437.64
215 rdf:type schema:Person
216 sg:person.01014260473.71 schema:affiliation grid-institutes:grid.410349.b
217 schema:familyName Sood
218 schema:givenName Ajay
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014260473.71
220 rdf:type schema:Person
221 sg:person.01030201361.33 schema:affiliation grid-institutes:grid.5288.7
222 schema:familyName Riddle
223 schema:givenName Matthew C.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030201361.33
225 rdf:type schema:Person
226 sg:person.01050764017.81 schema:affiliation grid-institutes:grid.39381.30
227 schema:familyName Hramiak
228 schema:givenName Irene
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050764017.81
230 rdf:type schema:Person
231 sg:person.010732071677.28 schema:affiliation grid-institutes:grid.410349.b
232 schema:familyName Ismail-Beigi
233 schema:givenName Faramarz
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010732071677.28
235 rdf:type schema:Person
236 sg:person.01227535066.58 schema:affiliation grid-institutes:grid.5386.8
237 schema:familyName Brillon
238 schema:givenName David J.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227535066.58
240 rdf:type schema:Person
241 sg:person.01351344021.39 schema:affiliation grid-institutes:grid.280807.5
242 schema:familyName Simmons
243 schema:givenName Debra L.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351344021.39
245 rdf:type schema:Person
246 sg:person.013715322252.30 schema:affiliation grid-institutes:grid.419635.c
247 schema:familyName Savage
248 schema:givenName Peter J.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013715322252.30
250 rdf:type schema:Person
251 sg:person.014063322564.84 schema:affiliation grid-institutes:grid.241167.7
252 schema:familyName Miller
253 schema:givenName Michael E.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014063322564.84
255 rdf:type schema:Person
256 sg:person.0622502703.19 schema:affiliation grid-institutes:grid.25073.33
257 schema:familyName Gerstein
258 schema:givenName Hertzel C.
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622502703.19
260 rdf:type schema:Person
261 sg:person.0651704421.35 schema:affiliation grid-institutes:grid.410711.2
262 schema:familyName Largay
263 schema:givenName Joseph F.
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651704421.35
265 rdf:type schema:Person
266 sg:person.0771130323.51 schema:affiliation grid-institutes:grid.25073.33
267 schema:familyName Punthakee
268 schema:givenName Zubin
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771130323.51
270 rdf:type schema:Person
271 grid-institutes:grid.241167.7 schema:alternateName Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, USA
272 schema:name Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, USA
273 rdf:type schema:Organization
274 grid-institutes:grid.25073.33 schema:alternateName Department of Medicine, McMaster University, 1280 Main St W., L8S 4K1, Hamilton, ON, Canada
275 schema:name Department of Medicine, McMaster University, 1280 Main St W., L8S 4K1, Hamilton, ON, Canada
276 rdf:type schema:Organization
277 grid-institutes:grid.280807.5 schema:alternateName VA Salt Lake City Health Care System, Salt Lake City, UT, USA
278 schema:name Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT, USA
279 VA Salt Lake City Health Care System, Salt Lake City, UT, USA
280 rdf:type schema:Organization
281 grid-institutes:grid.39381.30 schema:alternateName Department of Medicine, Western University, London, ON, Canada
282 schema:name Department of Medicine, Western University, London, ON, Canada
283 rdf:type schema:Organization
284 grid-institutes:grid.410349.b schema:alternateName Cleveland VA Medical Center, Cleveland, OH, USA
285 Louis Stokes VA Medical Center, Cleveland, OH, USA
286 schema:name Cleveland VA Medical Center, Cleveland, OH, USA
287 Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
288 Louis Stokes VA Medical Center, Cleveland, OH, USA
289 rdf:type schema:Organization
290 grid-institutes:grid.410711.2 schema:alternateName Division of Endocrinology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
291 schema:name Division of Endocrinology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
292 rdf:type schema:Organization
293 grid-institutes:grid.417226.4 schema:alternateName International Diabetes Center at Park Nicollet, Minneapolis, MN, USA
294 schema:name International Diabetes Center at Park Nicollet, Minneapolis, MN, USA
295 rdf:type schema:Organization
296 grid-institutes:grid.419635.c schema:alternateName National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
297 schema:name National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
298 rdf:type schema:Organization
299 grid-institutes:grid.5288.7 schema:alternateName Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA
300 schema:name Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA
301 rdf:type schema:Organization
302 grid-institutes:grid.5386.8 schema:alternateName Division of Endocrinology, Weill Cornell Medical College of Cornell University, New York, NY, USA
303 schema:name Division of Endocrinology, Weill Cornell Medical College of Cornell University, New York, NY, USA
304 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...